StevenYuenMD

Clinical Trials

• BG00012 Monotherapy Safety and Efficacy Extension Study in Multiple Sclerosis (MS) Start of enrollment: 2009 Feb 03

  Completed

  Phase 3

• A Study of Ocrelizumab in Participants With Primary Progressive Multiple Sclerosis Start of enrollment: 2011 Mar 02

  Completed

  Phase 3

• MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone Start of enrollment: 2012 Aug 09

  Terminated

  Phase 3

• The Study of Nasal Insulin in the Fight Against Forgetfulness (SNIFF) Start of enrollment: 2014 Jan 08

  Completed

  Phase 2, Phase 3

• An Efficacy and Safety Study of Lanabecestat (LY3314814) in Early Alzheimer's Disease Start of enrollment: 2014 Sep 30

  Terminated

  Phase 2, Phase 3

• Phase IIIB-IV Long-Term Follow-up Study for Patients Who Participated in CAMMS03409 Start of enrollment: 2015 Jan 07

  Completed

  Phase 4

• 221AD301 Phase 3 Study of Aducanumab (BIIB037) in Early Alzheimer's Disease Start of enrollment: 2015 Aug 13

  Terminated

  Phase 3

• An Efficacy and Safety Study of Atabecestat in Participants Who Are Asymptomatic at Risk for Developing Alzheimer's Dementia Start of enrollment: 2015 Oct 29

  Terminated

  Phase 2, Phase 3

• A Multi-Site, Open-Label Extension Trial of Oral RPC1063 in Relapsing Multiple Sclerosis Start of enrollment: 2015 Oct 16

  Completed

  Phase 3

• SUVN-502 With Donepezil and Memantine for the Treatment of Moderate Alzheimer's Disease- Phase 2a Study Start of enrollment: 2015 Sep 01

  Completed

  Phase 2

• A Study of Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (DMT) Start of enrollment: 2016 Feb 11

  Completed

  Phase 3

• Safety, Tolerability and Immunogenicity of ACI-24 Vaccine in Adults With Down Syndrome Start of enrollment: 2016 Mar 01

  Completed

  Phase 1

• A Study of Lanabecestat (LY3314814) in Participants With Mild Alzheimer's Disease Dementia Start of enrollment: 2016 Jul 01

  Terminated

  Phase 3

• Efficacy and Safety of Ofatumumab Compared to Teriflunomide in Patients With Relapsing Multiple Sclerosis Start of enrollment: 2016 Sep 20

  Completed

  Phase 3

• Alzheimer's Disease Neuroimaging Initiative 3 (ADNI3) Start of enrollment: 2016 Oct 01

  Recruiting

• Effect of MD1003 in Progressive Multiple Sclerosis (SPI2) Start of enrollment: 2016 Dec 01

  Terminated

  Phase 3

• Phase 2 Study of BIIB092 in Participants With Early Alzheimer's Disease Start of enrollment: 2018 May 03

  Terminated

  Phase 2

• A Study of LY3002813 in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ) Start of enrollment: 2017 Dec 18

  Completed

  Phase 2

• Safety and Efficacy Study of Gantenerumab in Participants With Early Alzheimer's Disease (AD) Start of enrollment: 2018 Aug 22

  Terminated

  Phase 3

• Traditional Versus Early Aggressive Therapy for Multiple Sclerosis Trial Start of enrollment: 2018 May 02

  Recruiting

  Not Applicable

• Study of BHV-4157 in Alzheimer's Disease Start of enrollment: 2018 Jul 31

  Completed

  Phase 2

• ADvance II Study: DBS-f in Patients With Mild Alzheimer's Disease Start of enrollment: 2019 Aug 01

  Active, not recruiting

  Not Applicable

• A Study to Assess the Safety and Efficacy of Elezanumab When Added to Standard of Care in Relapsing Forms of Multiple Sclerosis Start of enrollment: 2018 Dec 11

  Completed

  Phase 2

• Join now to see all